Clinical trials: Zoledronic acid
Mesothelioma
Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG…
- Trial name
- UAB0901 (NCT01204203)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Alabama at Birmingham
Bone Marrow Edema
Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome
The primary aim is to test the reduction of bone marrow edema syndrome after a singular intravenous treatment with Zoledronic Acid within 6 weeks compared to placebo.
- Trial name
- ZoMARS (NCT01348269)
- Testing
- Aclasta
- Where
- 2 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Wuerzburg University Hospital
Multiple Myeloma
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
- Trial name
- NCT01234129
- Testing
- zoledronic acid
- Where
- Mexico
- Volunteers
- 320 people
- Sponsor
- Instituto Mexicano del Seguro Social
Prostate Cancer
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma.
- Trial name
- NCT00582556
- Testing
- Zometa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Wisconsin, Madison
Osteoporosis
Zometa Study in Pediatric Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in children. It accounts for one fourth of all childhood cancers \& 74 % of childhood leukemia.
- Trial name
- NCT01656512
- Testing
- zolendronic acid, calcium & vitamin D
- Where
- Egypt
- Volunteers
- 95 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Bone Loss
Bone Loss Treatment From Adjuvant Zoledronate Efficacy
The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on bone density in breast cancer patients.
- Trial name
- BLAZE (NCT01623908)
- Testing
- Zoledronate
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Metastatic Breast Cancer, Bone Metastases
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis
The primary objective of this study is to evaluate the effects of Zometa (zoledronic acid, 1 mg per week versus 4 mg every four weeks) on the circulating vascular endothelial growth factor (VEGF) levels in breast cancer patients…
- Trial name
- NCT00524849
- Testing
- Zoledronic acid
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Metastatic Breast Cancer With Bone Involvement
Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect
Bone is the most common site of spread of breast cancer and bone metastases will occur in roughly 70% of women with advanced disease.
- Trial name
- SuBDuE (NCT01344967)
- Testing
- Zoledronic acid
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University Health Network, Toronto
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Osseous Lesions From Metastatic Breast Cancer
Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer
The purpose of this study is to examine for changes in the bone scan after treating with zoledronic acid (Zometa™). This study is designed to show if intravenous (IV) bisphosphonates, which are infused by vein, such as…
- Trial name
- NCT00582920
- Testing
- Zometa™
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoporosis, Osteoporosis, Postmenopausal
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
This two-year observational, open-label clinical trial will evaluate the efficacy of a once-yearly infusion of zoledronic acid after denosumab discontinuation to maintain tissue mineral density and bone microarchitecture using…
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Osteopenia, Bone Loss
- Trial name
- NCT05405894
- Testing
- Zoledronic acid
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Osteogenesis Imperfecta
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Osteogenesis imperfecta (OI) is an inherited skeletal disorder characterised by increased risk of fragility fractures. Bisphosphonates are frequently prescribed for adult patients with OI with the aim of preventing fractures but…
- Trial name
- TOPaZ (NCT03735537)
- Testing
- Teriparatide Pen Injector, Zoledronic Acid
- Where
- 23 sites in Ireland, United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Edinburgh
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%)…
- Conditions
- Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03073785
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
IOP, Osteoporosis
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
The primary goal of the study is to assess the extent to which bisphosphonate therapy will prevent decreases in bone mass that may occur after cessation of denosumab in premenopausal women with idiopathic osteoporosis (IOP)…
- Trial name
- NCT03396315
- Testing
- Alendronate, Zoledronic Acid
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Columbia University
Hip Osteoarthritis
Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis
This is a randomized, double-blind and placebo-controlled study to evaluate the efficacy of zoledronic acid on the biologic incorporation of cementless hip prosthesis in postmenopausal female patients.The study population…
- Trial name
- NCT01218035
- Testing
- zoledronic acid
- Where
- Finland
- Volunteers
- 49 people
- Sponsor
- Turku University Hospital
Bone Metastases
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
- Trial name
- NCT00321464
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 2,049 people
- Sponsor
- Amgen
Kidney Cancer, Metastatic Cancer
Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00588913
- Testing
- aldesleukin, therapeutic autologous lymphocytes, zoledronic acid
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Tokyo Women's Medical University
Multiple Myeloma
Prolonged Protection From Bone Disease in Multiple Myeloma
Main hypothesis: Patients who continue zoledronic acid after year 2 have longer time until progression in bone disease compared to patients who stop treatment after two years? Secondary hypothesis: Serum will bone markers…
- Trial name
- Magnolia (NCT02286830)
- Testing
- Zoledronic acid
- Where
- Denmark
- Volunteers
- 158 people
- Sponsor
- Thomas Lund
Osteopenia
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
Zoledronic acid is a medicine being studied in people with low bone mass. Side effects such as headache, fever, muscle aches, and pains, may occur following the infusion.
- Trial name
- NCT00145275
- Testing
- zoledronic acid
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 455 people
- Sponsor
- Novartis